GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Biomea Fusion Inc.
The shares of Biomea Fusion, a biotech company focused on treating diabetes and cancer, reflect the potential of its innovative platform. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma metabolism
Biomea Fusion is a biopharmaceutical company developing irreversible small-molecule drugs for the treatment of metabolic diseases and cancer. We classify it as "Pharmaceuticals (Metabolism)." The chart below shows the overall dynamics of this innovative biotech segment.
Broad Market Index - GURU.Markets
Biomea Fusion is a biopharmaceutical company developing irreversible small-molecule drugs for the treatment of cancer and diabetes. Its cutting-edge approach makes it a component of the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
BMEA - Daily change in the company's share price Biomea Fusion Inc.
For Biomea Fusion, Inc., a biotechnology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Biomea Fusion, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with BMEA, which focuses on diabetes and cancer treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Biomea Fusion is a biotech company developing drugs to treat metabolic diseases and cancer. Its shares are driven by news of scientific progress. This high volatility, driven by innovation, is a significant contributor to the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Biomea Fusion Inc.
For Biomea Fusion, Inc., the year-over-year trend is a story about developing a new class of covalent inhibitors for the treatment of diabetes and cancer. Its 12-month market cap is entirely dependent on early clinical trial data. Positive results could confirm the breakthrough potential of its platform and lead to explosive growth.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Biomea Fusion is a clinical-stage biotech company developing a new class of drugs for the treatment of cancer and diabetes. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biomea Fusion is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Biomea Fusion Inc.
Biomea Fusion is a biotech company developing small-molecule drugs. Its monthly growth is entirely dependent on progress in its clinical trials. Positive safety and efficacy data presented at scientific conferences trigger sharp increases, typical of early-stage biotech.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Biomea Fusion is a biopharmaceutical company developing irreversible small molecule inhibitors for the treatment of oncology and metabolic diseases such as diabetes. The graph below illustrates the overall dynamics in the pharmaceutical sector, reflecting the search for new approaches to creating more durable and effective drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biomea Fusion is a clinical-stage biotech developing drugs to treat diabetes and cancer. Its stock is a bet on scientific success. Any news about the progress of trials can trigger a dramatic rise or fall, completely ignoring overall market trends. The chart clearly illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Biomea Fusion Inc.
The weekly performance of Biomea Fusion, a biotech company targeting diabetes and oncology, reflects the potential of its innovative platform. Shares are reacting strongly to preclinical and clinical data that could confirm the efficacy of their irreversible inhibitors.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Biomea Fusion is developing covalent inhibitors for the treatment of cancer and diabetes. This is a cutting-edge, yet risky, approach in pharmaceuticals. The chart below is your guide: are the company's weekly stock fluctuations driven by its own scientific data, or do they reflect the general hopes and fears of investors across the biotech industry?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biomea Fusion is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Biomea is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
BMEA - Market capitalization of the company Biomea Fusion Inc.
Biomea Fusion's market capitalization tells the story of a biotech company developing a new class of irreversible inhibitors for the treatment of cancer and diabetes. Its volatile price chart reflects the high interest in its scientific platform. Its volatility reflects investors' appreciation of its promising early data and the enormous potential if its approach proves successful.
BMEA - Share of the company's market capitalization Biomea Fusion Inc. within the market segment - Pharma metabolism
Biomea Fusion is a clinical-stage biotech developing irreversible small-molecule inhibitors for the treatment of cancer and diabetes. Its market cap reflects the potential of its innovative scientific platform. The chart below shows the market's bet on its ability to create breakthrough drugs for difficult-to-treat diseases.
Market capitalization of the market segment - Pharma metabolism
Biomea Fusion is a clinical-stage biotech company developing a new class of drugs for the treatment of cancer and diabetes. The chart below shows the overall market capitalization of this sector. Its volatility reflects investors' high hopes for a scientific breakthrough that could transform the treatment of these common diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Biomea Fusion is a biotech company developing irreversible inhibitors for the treatment of cancer and diabetes. Its market cap reflects its unique scientific approach. Its volatility on the overall chart reflects how the market perceives the potential of this new technology, which could transform the treatment of these diseases.
Book value capitalization of the company, segment and market as a whole
BMEA - Book value capitalization of the company Biomea Fusion Inc.
Biomea Fusion's book value is the capital invested in the development of innovative small molecules that irreversibly bind to their targets for the treatment of cancer and diabetes. This is the tangible, scientific foundation for a new therapeutic approach. How has this biotech asset changed? The chart below shows its dynamics.
BMEA - Share of the company's book capitalization Biomea Fusion Inc. within the market segment - Pharma metabolism
Biomea Fusion develops irreversible inhibitors for the treatment of cancer and diabetes, which requires R&D laboratories. The chart shows the share of these science-intensive material assets, reflecting the physical foundation of its innovative chemical platform.
Market segment balance sheet capitalization - Pharma metabolism
Biomea Fusion is a clinical-stage biotech company. Its value lies in its development potential, not its manufacturing facilities. A book-to-market capitalization chart will show how "light" its capital base is, which is typical for the R&D sector.
Book value of all companies included in the broad market index - GURU.Markets
Biomea Fusion develops irreversible inhibitors for cancer treatment. Its book value is derived from its cutting-edge FUSION platform, laboratories, and capital for clinical development. The chart shows the material foundation on which this new frontier in targeted therapy is being built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Biomea Fusion Inc.
Biomea Fusion's balance sheet is capital. But the market sees a revolutionary platform for drug discovery. The chart shows a colossal "hope factor": a premium for the potential of its irreversible binding technology to defeat cancer and diabetes.
Market to book capitalization ratio in a market segment - Pharma metabolism
Biomea Fusion is a biotech company developing a new class of covalent inhibitors for the treatment of cancer and diabetes. Its valuation is entirely dependent on the success of its scientific platform. The chart demonstrates the high expectations investors have for this innovative technology.
Market to book capitalization ratio for the market as a whole
Biomea Fusion is a biotech company developing irreversible small molecule inhibitors for the treatment of cancer and diabetes. Their approach is to create drugs that bind permanently to their target. This chart shows the overall valuation, but how does the market value a company that uses advanced chemistry to create more potent drugs?
Debts of the company, segment and market as a whole
BMEA - Company debts Biomea Fusion Inc.
Biomea Fusion, a clinical-stage biotech company, is developing a new class of drugs. This chart shows how it funds its expensive research. It's a high-risk financial strategy based on the belief that its scientific approach will lead to breakthrough targeted therapies.
Market segment debts - Pharma metabolism
Biomea Fusion is a biotech company developing irreversible inhibitors for the treatment of cancer and metabolic diseases. This approach is cutting-edge scientific. This chart shows how the company is raising capital to fund its unique and expensive preclinical and clinical research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Biomea Fusion Inc.
Biomea Fusion is a biotech company developing drugs to treat metabolic diseases and cancer. This chart shows its reliance on external financing. For such a company, debt is a way to accelerate expensive clinical trials, and its level reflects both the ambition and the financial risks involved in developing a cure.
Market segment debt to market segment book capitalization - Pharma metabolism
Biomea Fusion is a biopharmaceutical company developing irreversible small molecule inhibitors for the treatment of cancer and metabolic diseases. This chart shows the overall debt burden in the biotech sector, helping to understand how the industry finances its innovative platforms and expensive clinical trials.
Debt to book value of all companies in the market
Biomea Fusion is a biopharmaceutical company developing irreversible inhibitors for cancer treatment. Currently in clinical trials, it is financed exclusively by equity. This market-wide debt load chart stands in stark contrast to the biotech world, where equity is a bet on scientific breakthroughs, not leverage.
P/E of the company, segment and market as a whole
P/E - Biomea Fusion Inc.
For Biomea Fusion, a biopharmaceutical company developing covalent inhibitors, this chart illustrates investor expectations. Its significance is based not on profits, but on the potential of its innovative platform for developing targeted drugs for the treatment of cancer and metabolic diseases such as diabetes.
P/E of the market segment - Pharma metabolism
The targeted cancer therapy being developed by Biomea Fusion is personalized medicine. This chart shows the average rating for biopharmaceutical companies. It helps to understand that Biomea, with its covalent inhibitor technology, is considered a scientific platform capable of developing new classes of drugs.
P/E of the market as a whole
Biomea Fusion, Inc. is a biopharmaceutical company developing irreversible small-molecule drugs for the treatment of cancer and metabolic diseases such as diabetes. It offers an innovative chemistry-based approach. This biotech sentiment chart helps understand how the market views Biomea's scientific platform and its potential for creating breakthrough drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Biomea Fusion Inc.
Biomea Fusion is a clinical-stage biotech developing covalent inhibitors for the treatment of cancer and diabetes. This chart reflects the high but risky expectations of its innovative scientific platform. The trend represents investor assessments of the likelihood of success for its clinical programs.
%20P%2FE%20Biomea%20Fusion%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Biomea-Fusion-Inc.&v=1772619240851 "Chart of the company's future (projected) P/E Biomea Fusion Inc.")
Future (projected) P/E of the market segment - Pharma metabolism
Biomea Fusion is a biotech company developing irreversible covalent inhibitors for the treatment of cancer and metabolic diseases such as diabetes. This chart shows profitability expectations for the sector. It helps understand how highly the market values the company's scientific approach and the potential of its platform for drug discovery.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772619240859 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Biomea Fusion, Inc. is a biopharmaceutical company developing covalent inhibitors for the treatment of cancer and diabetes. This chart shows investors' risk appetite. For a company with an innovative chemistry platform, it reflects the market's willingness to invest in new approaches to creating targeted drugs with potentially high efficacy.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772619240873 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Biomea Fusion Inc.
Biomea Fusion, Inc. is a clinical-stage biotechnology company developing irreversible inhibitors for the treatment of cancer and metabolic diseases. The financial metrics presented here reflect research expenses. The chart illustrates the cost of developing a new class of targeted drugs with a unique mechanism of action.
Profit of companies in the market segment - Pharma metabolism
Biomea Fusion is a biopharmaceutical company developing irreversible small-molecule inhibitors for the treatment of oncology and metabolic diseases such as diabetes. Its approach is aimed at creating more durable and effective drugs. This chart illustrates how advanced chemistry and new approaches to drug development can create enormous profit potential in the pharmaceutical industry.
Overall market profit
Biomea Fusion is a biotech company developing a new class of irreversible inhibitors for the treatment of cancer and diabetes. This is at the cutting edge of science, and the company's success depends on the results of clinical trials. This overall market return chart provides the backdrop against which investors make funding decisions for such risky but potentially breakthrough projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Biomea Fusion Inc.
Biomea Fusion is a clinical-stage biopharmaceutical company developing irreversible small-molecule inhibitors for the treatment of cancer and diabetes. The earnings forecast in this chart reflects analyst expectations for its innovative scientific platform and clinical trial results.
%20profit%20of%20the%20company%20Biomea%20Fusion%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Biomea-Fusion-Inc.&v=1772619240926 "Graph of future (projected) profit of the company Biomea Fusion Inc.")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Biomea Fusion is a biopharmaceutical company developing irreversible covalent inhibitors for the treatment of cancer and metabolic diseases such as diabetes. This approach is cutting-edge chemistry. This chart shows the revenue forecast for the metabolic pharma sector, allowing one to assess the market's perception of the potential of Biomea Fusion's innovative platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772619241001 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Biomea Fusion is a biotech company developing small-molecule drugs for cancer treatment. Its future depends on the success of clinical trials. This graph, reflecting investor risk appetite, impacts the availability of capital for long-term, high-risk projects in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772619241068 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Biomea Fusion Inc.
Biomea Fusion is a biopharmaceutical company developing irreversible small molecule inhibitors for the treatment of cancer and diabetes. This chart reflects investor expectations for its innovative platform. The valuation is a bet that its unique chemistry will lead to breakthrough drugs.
P/S market segment - Pharma metabolism
Biomea Fusion is a biopharmaceutical company developing a new class of irreversible small molecule inhibitors for the treatment of cancer and metabolic diseases such as diabetes. This chart shows the industry average market capitalization to revenue ratio, reflecting how investors view the potential of Biomea's innovative scientific platform.
P/S of the market as a whole
Biomea Fusion is a clinical-stage biopharmaceutical company developing irreversible covalent inhibitors for the treatment of cancer and metabolic diseases such as diabetes. This approach is cutting-edge chemistry. This chart helps understand how the market values science-intensive biotech companies whose technology can be applied to several serious diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Biomea Fusion Inc.
Biomea Fusion is a clinical-stage biopharmaceutical company developing irreversible inhibitors for the treatment of cancer and diabetes. This chart shows its valuation relative to future, hypothetical, sales. It reflects investors' confidence in the potential of its scientific platform to create breakthrough drugs.
%20P%2FS%20Biomea%20Fusion%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Biomea-Fusion-Inc.&v=1772619241207 "The graph of the company's future (projected) P/S Biomea Fusion Inc.")
Future (projected) P/S of the market segment - Pharma metabolism
Biomea Fusion is a clinical-stage biopharmaceutical company developing irreversible small-molecule therapeutics for the treatment of metabolic diseases and cancer. Its unique approach targets difficult-to-treat diseases. This chart reflects the high investor expectations for its scientific platform and potential future sales.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772619241246 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Biomea Fusion is a biotech company developing covalent inhibitors for the treatment of cancer and diabetes. Its value is entirely dependent on the success of its scientific platform and clinical trials. This graph of overall expectations for BMEA is merely a backdrop. The company's value is determined by faith in its technology, not the overall economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772619241266 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Biomea Fusion Inc.
This chart illustrates the financial trajectory of a biotech company. For Biomea Fusion, which develops covalent inhibitors for the treatment of cancer and diabetes, it reflects funds raised from investors to fund clinical trials, not commercial revenue from sales.
Sales of companies in the market segment - Pharma metabolism
Biomea Fusion is a clinical-stage biopharmaceutical company developing irreversible inhibitors for the treatment of cancer and diabetes. Its innovative platform has the potential to create new drugs. This chart shows revenue in the pharmaceutical sector. Biomea's potential success in treating type 2 diabetes could be a breakthrough and radically change the market.
Overall market sales
Biomea Fusion is a biotechnology company developing irreversible small molecule inhibitors for the treatment of cancer and diabetes. This cutting-edge scientific approach is at the forefront of the company's research. The company's success in clinical trials could lead to the creation of new classes of drugs and demonstrates how fundamental science advances medicine and creates new economic opportunities.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Biomea Fusion Inc.
Biomea Fusion is a biotechnology company developing irreversible small molecule inhibitors for the treatment of oncology and metabolic diseases such as diabetes. Future sales projections depend on the success of its innovative scientific platform.
%20sales%20of%20the%20company%20Biomea%20Fusion%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Biomea-Fusion-Inc.&v=1772619241345 "Schedule of future (projected) sales of the company Biomea Fusion Inc.")
Future (projected) sales of companies in the market segment - Pharma metabolism
Biomea Fusion, Inc. is a biopharmaceutical company developing irreversible inhibitors for the treatment of cancer and diabetes. The forecast for the metabolism and oncology pharmaceutical sector shows enormous potential. The chart illustrates the size of the market for breakthrough drugs capable of changing the course of these diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772619241364 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Biomea Fusion is a biopharmaceutical company developing irreversible small-molecule inhibitors for the treatment of cancer. Its prospects depend entirely on the success of clinical trials. The overall economic situation, reflected in this chart, does not affect the need for treatment but is important for assessing the investment attractiveness and capital availability of biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772619241404 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Biomea Fusion Inc.
Biomea Fusion is a biotech company developing drugs to treat metabolic diseases and cancer. Currently in the clinical stage, it is entirely focused on research. This chart shows the investment in its development pipeline, not revenue, which is typical for innovative companies in this field.
Market segment marginality - Pharma metabolism
Biomea Fusion is a biotechnology company developing irreversible small-molecule therapeutics for the treatment of cancer and metabolic diseases. Profitability is a future goal, dependent on the success of its innovative platform. This metric reflects the structure of its research investments relative to other oncology and metabolic companies.
Market marginality as a whole
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company developing a new class of covalent drugs for the treatment of cancer and diabetes. This chart reflects average returns. Compared to this, Biomea is a high-risk bet on an innovative scientific platform. The company is not profitable and is investing in research to create breakthrough drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Biomea Fusion Inc.
Biomea Fusion is a biotech company developing irreversible inhibitors for the treatment of cancer and diabetes. Its team of scientists is its greatest asset. The growth seen in this chart directly correlates with the progress of its unique FUSION platform and the expansion of clinical trials for its promising drug candidates.
Share of the company's employees Biomea Fusion Inc. within the market segment - Pharma metabolism
Biomea Fusion is a clinical-stage biopharmaceutical company developing irreversible small-molecule inhibitors for the treatment of cancer and metabolic diseases. This chart shows its scientific breakthroughs. It reflects the percentage of medicinal chemists and biologists working on this cutting-edge class of drugs Biomea attracts.
Number of employees in the market segment - Pharma metabolism
Biomea Fusion develops irreversible small-molecule drugs for the treatment of cancer and diabetes. This graph illustrates cutting-edge research in drug chemistry. The growth of the research team here signifies progress in creating a new class of drugs that can provide a more potent and long-lasting therapeutic effect.
Number of employees in the market as a whole
Biomea Fusion, Inc. is a biotech company developing drugs to treat metabolic diseases and cancer. Their path is driven by scientific discoveries, not macroeconomic indicators, as reflected in this chart. A successful clinical trial phase could lead to a sharp increase in the company's value and expansion of its research staff.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Biomea Fusion Inc. (BMEA)
Biomea Fusion is a biotech company developing irreversible small-molecule drugs for cancer treatment. This is a cutting-edge approach to targeted therapy. This chart shows how investors value scientific innovation. The astronomical market capitalization per employee reflects the enormous potential of their unique chemistry platform for creating breakthrough drugs.
%20of%20the%20company%20Biomea%20Fusion%20Inc.%20(BMEA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Biomea-Fusion-Inc.-BMEA&v=1772619241580 "Chart of market capitalization per employee (in thousands of dollars) of the company Biomea Fusion Inc. (BMEA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Biomea Fusion is a biotech company developing drugs to treat cancer and diabetes. Its market capitalization reflects investors' bets on a scientific breakthrough. This chart clearly demonstrates how highly the market values the team's intellectual capital. Every employee contributes to the potentially multibillion-dollar value of future drugs.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772619241646 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Biomea Fusion is a biopharmaceutical company developing irreversible inhibitors for the treatment of cancer and diabetes. This chart shows the company's high employee rating, as its innovative scientific approach could lead to the creation of a new class of highly effective drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772619241752 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Biomea Fusion Inc. (BMEA)
Biomea Fusion is a biotech company developing irreversible (covalent) inhibitors for the treatment of cancer and, more recently, diabetes. This is cutting-edge R&D. This metric is negative and reflects the company's "burn rate." It shows how much the company spends on each scientist to develop this new class of drugs and conduct clinical trials.
%20Chart%20Biomea%20Fusion%20Inc.%20(BMEA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Biomea-Fusion-Inc.-BMEA&v=1772619241780 "Company Profit Per Employee (in thousands of dollars) Chart Biomea Fusion Inc. (BMEA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Biomea Fusion (BMEA) is a biotech company developing irreversible inhibitors for the treatment of cancer and diabetes. For a clinical-stage company, this schedule is a theoretical benchmark. All of BMEA's current operations are unprofitable and focused on research. Success would mean their team has created a drug that will generate profits above industry standards.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772619241809 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Biomea Fusion (BMEA) is a biotech company developing irreversible inhibitors for the treatment of cancer and diabetes. It is a clinical-stage R&D company. Negative profit per employee is the norm. The graph shows the "cost" of a team of scientists working on a breakthrough, but not yet commercialized, technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772619241867 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Biomea Fusion Inc. (BMEA)
Biomea Fusion is a clinical-stage biotech company developing drugs for the treatment of cancer and diabetes. This chart reflects its focus on research. Lack of revenue is normal. This metric demonstrates enormous potential: a successful drug could lead to explosive growth in revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Biomea-Fusion-Inc.-BMEA&v=1772619241874 "Sales chart per company employee Biomea Fusion Inc. (BMEA)")
Sales per employee in the market segment - Pharma metabolism
Biomea Fusion is a biotech company developing irreversible inhibitors (covalent drugs) for the treatment of cancer and diabetes. This is a cutting-edge R&D company. At the clinical trial stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee.
Sales per employee for the market as a whole
Biomea Fusion is a clinical-stage biotech company developing covalent inhibitors for the treatment of cancer and diabetes. It is a 100% R&D company. This chart shows revenue per employee, which, as expected, is zero. It emphasizes that the company does not sell products but invests in lengthy and expensive clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Biomea Fusion Inc. (BMEA)
Biomea Fusion is a clinical-stage biotech developing irreversible small-molecule inhibitors for the treatment of cancer and diabetes. This chart shows bearish bets. Bears may be concerned about recent toxicity data from its drugs in trials or believe its approach will not prove effective, which is a high risk.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Biomea-Fusion-Inc.-BMEA&v=1772619241893 "Short Shares Chart for the Company Biomea Fusion Inc. (BMEA)")
Shares shorted by market segment - Pharma metabolism
Biomea Fusion is a biotech company developing irreversible small-molecule inhibitors for the treatment of cancer and diabetes. This chart shows overall short positions in the biotech sector. A high reading reflects general market skepticism about the sector, possibly due to fears of research failures or funding difficulties.
Shares shorted by the overall market
Biomea Fusion (BMEA) is a clinical-stage biotech. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Biomea Fusion Inc. (BMEA)
Biomea Fusion is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can soar above 70 on positive R&D data, but this is high-risk territory. Oversold territory (<30) often reflects setbacks, safety concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Biomea-Fusion-Inc.-BMEA&v=1772619242004 "RSI 14 indicator chart for the company's stock Biomea Fusion Inc. (BMEA)")
RSI 14 Market Segment - Pharma metabolism
Biomea (BMEA) is one of the hottest biotechs in the race for diabetes drugs (a GLP-1 competitor). The "Pharma Metabolism" sector is the epicenter of the hype. The RSI_14_Seg index for this segment is a barometer of overheating. It's vital to understand whether BMEA's wild volatility is due to its R&D or whether the entire sector is simply overheated.
RSI 14 for the overall market
For Biomea Fusion, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BMEA (Biomea Fusion Inc.)
Biomea Fusion is a clinical-stage biotech developing covalent inhibitors (BMF-219) with breakthrough potential for the treatment of diabetes. This chart shows the average target price. Analysts' forecasts are based on clinical data and the market potential of this oral diabetes medication.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BMEA-Biomea-Fusion-Inc.&v=1772619242050 "A chart showing analyst consensus forecasts for the expected stock price. BMEA (Biomea Fusion Inc.)")
The difference between the consensus estimate and the actual stock price BMEA (Biomea Fusion Inc.)
Biomea Fusion is a biotech company developing innovative covalent inhibitors for the treatment of cancer and type 2 diabetes. This chart shows the upside and downside potential analysts see for the stock. For BMEA, this gap reflects the experts' faith in their breakthrough science, particularly their diabetes data (BMF-219).
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BMEA-Biomea-Fusion-Inc.&v=1772619242109 "A chart showing the difference between the consensus forecast and the actual stock price. BMEA (Biomea Fusion Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Biomea Fusion is a biotech company developing next-generation drugs for diabetes and cancer. This chart reflects analysts' overall expectations for the entire metabolic drug sector. It shows whether experts believe the obesity drug boom will continue or whether they believe the entire sector is already overheated.
Analysts' consensus forecast for the overall market share price
Biomea Fusion (BMEA) is a clinical-stage biopharmaceutical company working on breakthroughs in the treatment of type 2 diabetes and cancer. They are developing drugs that aim to "turn off" the disease. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough, but extremely risky, R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Biomea Fusion Inc.
Biomea Fusion is a biotech company working on irreversible (covalent) drugs. Their R&D platform is aimed at disabling proteins that cause cancer and, to great acclaim, metabolic diseases (like diabetes). This chart is a clear indicator of their R&D confidence. Its dynamics are entirely dependent on their clinical data and the market's faith in their breakthrough scientific platform.
AKIMA Market Segment Index - Pharma metabolism
Biomea Fusion is a biotech company developing irreversible (covalent) inhibitors for the treatment of cancer and metabolic diseases such as diabetes. This chart shows the average index for the pharmaceutical sector. It allows one to assess how Biomea's innovative scientific approach distinguishes itself from the average pharmaceutical company.
The AKIM Index for the overall market
Biomea Fusion is a biotech company developing covalent small molecules to treat diabetes and cancer. Its approach is aimed at beta cell regeneration. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative but high-risk scientific story compares to overall economic trends and sector sentiment.
